key: cord-0050000-vsfio8h0 authors: Ky, Bonnie title: Reflections on Our Inaugural Year of JACC: CardioOncology, With Gratitude and Tireless Devotion date: 2020-09-15 journal: JACC CardioOncol DOI: 10.1016/j.jaccao.2020.08.002 sha: 8f456088fb74a80ae6b43fcf13b2abb69d06c662 doc_id: 50000 cord_uid: vsfio8h0 nan ; and the intersection between cardiovascular disease and cancer in our patients (17) (18) (19) . In the second quarter of 2020 alone, we had nearly 130,000 article usage sessions, and each quarter, this number has grown. The work of our authors is being read for utilization in clinical practice and research, which is always the most important metric for a JACC journal. As a physician scientist, I recognize that the choice of "which journal" is not an easy one and requires careful consideration. We remain committed to serving our authors and working tirelessly to ensure that the peer review process is respectful, fair, constructive, and as seamless as possible. Our average time to first decision in second quarter 2020 was 15 days, and we will strive to maintain this standard. We seek to partner and work collaboratively with our authors to ensure the high- Over the next year, we will improve access to JACC: CardioOncology through additional platform changes to improve searchability and integration across the JACC Journals. Clinical, translational, and basic science original research manuscripts will continue to serve as our foundation. As we evaluate each manuscript, we will continue to ask ourselves the following key questions: Are the findings valid? Is the methodology rigorous? Is the topic of clinical importance? Are the findings incremental to our current understanding of the topic and do they fulfill an evidence gap? What is the potential clinical impact and the potential for advancing the field? We will continue to publish State-of-the-Art Reviews and Primers, and similarly ask ourselves: is this an authoritative, critical appraisal of the literature? Is it comprehensive, yet focused? Is this data-driven and accurately reflective of the current evidence? We will look to Clinical Case Challenges to provide evidence-based descriptions of unique cases that thoughtfully illustrate the diagnostic and therapeutic dilemmas that we as clinicians face as we care for our patients (20) . Our Viewpoints will continue to express opinion pieces on important and timely topics, and present thought-provoking, community-building, evidence-based perspectives. We will continue to grow our international engagement events, podcasts, live Journal clubs, and dynamic case presentations, each occurring at least once per quarter. We also will launch a new "How To" series that will offer practical, evidencebased education on common clinical questions that are relevant to the everyday cardiovascular care of our cancer patients. I am grateful. I serve a wonderful community, one made of patients, physicians, scientists, and care providers who inspire and motivate me daily. I look forward to continuing to work with a tireless devotion to "never feeling satisfied"-in our mission to educate our global community and positively impact the care of our patients. cardiovascular disease and cancer COVID-19 clinical trials: a primer for the cardiovascular and cardiooncology communities AL amyloidosis for the cardiologist and oncologist Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer Repeated remote ischemic conditioning reduces doxorubicin-induced cardiotoxicity Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS) Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor CAR T-cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? Cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE trial study design Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management Increased cancer prevalence in peripartum cardiomyopathy Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention Infiltrative lymphoma-associated bradycardia and cardiac conduction abnormalities